PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well as syngeneic tumor models treated with Newcastle disease virus (NDV) to ide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation Jg. 128; H. 4; S. 1413 - 1428
Hauptverfasser:	Zamarin, Dmitriy, Ricca, Jacob M., Sadekova, Svetlana, Oseledchyk, Anton, Yu, Ying, Blumenschein, Wendy M., Wong, Jerelyn, Gigoux, Mathieu, Merghoub, Taha, Wolchok, Jedd D.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States American Society for Clinical Investigation 01.04.2018
Schlagworte:	Analysis Apoptosis Biomedical research Cancer therapies Care and treatment Cell death Clinical trials Drug therapy Genes Health aspects Immunotherapy Infections Interferon Ligands Lymphocytes Lymphocytes T Melanoma Metastases Metastasis Newcastle disease Oncolysis Patient outcomes PD-1 protein PD-L1 protein Skin cancer Therapeutic targets Tumors Viruses United States Oncology Immunology Gene therapy T cells Immunotherapy
ISSN:	0021-9738, 1558-8238, 1558-8238
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!